Biocon Biologics Eyes USD 75 Billion Oncology Market, Adds 3 New Biosimilar Drugs
These products are among the largest oncology biologics expected to lose exclusivity over the next five years.
Bengaluru: Biocon Biologics Ltd, a subsidiary of Biocon Limited, has announced plans to expand its biosimilar oncology portfolio with three new proposed assets and outlined its strategic vision, including corporate integration plans, at the 44th Annual J.P. Morgan Healthcare Conference 2026 in San Francisco.
The company said it will introduce proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®).
With the addition of these assets, including two PD-1 inhibitors, Biocon Biologics aims to build one of the most comprehensive oncology biosimilar portfolios in the industry, enabling broader access to critical cancer therapies through cost-effective alternatives. In 2024, global sales of Keytruda stood at USD 29.5 billion, Opdivo at USD 9.3 billion, while Herceptin SC and Herceptin HYLECTA together recorded sales of USD 1.72 billion.
These products are among the largest oncology biologics expected to lose exclusivity over the next five years.
The new assets will add to Biocon Biologics’ existing portfolio of 17 oncology medicines, which includes Pertuzumab (Perjeta®), recently submitted to the US FDA, along with several small-molecule cancer therapies. Overall, the company’s oncology portfolio, including undisclosed products, represents an opportunity of over USD 75 billion, accounting for approximately 35% of the global oncology pharmaceutical market.
The announcement also highlighted Biocon Limited’s plan to integrate Biocon Biologics as a wholly owned subsidiary, a process expected to be completed by March 31, 2026. The integration is intended to simplify the corporate structure, leverage global commercial infrastructure, and strengthen Biocon’s leadership across diabetes, oncology, and immunology—therapeutic areas that together account for nearly 40% of global pharmaceutical revenues. Following the integration and subject to necessary approvals, Shreehas Tambe will take on the role of CEO and Managing Director of the combined business.
According to the company, the integration will uniquely position Biocon as the only organisation offering both biosimilar insulins and complex peptide generics, including GLP-1s, covering the full spectrum of diabetes care. It is also expected to enhance Biocon Biologics’ ability to deliver innovative and affordable medicines to over 6 million patients across more than 120 markets worldwide.
Commenting on the development, Shreehas Tambe said the integration with Biocon Limited would strengthen the company’s ability to deliver biosimilars and generics at global scale, while advancing a strong oncology pipeline through a science-led research and development approach.
Also Read: Biocon Biologics gains full gobal rights to biosimilar Adalimumab
